Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. News
  7. Summary
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/18
40.48 AUD   -1.53%
10/17CLINUVEL PHARMACEUTICALS : Investor Webinar
PU
10/06CLINUVEL PHARMACEUTICALS : Operations Update Webcast II
PU
10/05Australia shares nearly flat as financials' losses offset tech, healthcare gains
RE
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Clinuvel Pharmaceuticals : Key Events and Announcements

09/22/2021 | 07:52pm EDT

C O M P A N Y A N N O U N C E M E N T

CLINUVEL KEY EVENTS

AND ANNOUCEMENTS

ASX:

CUV

Melbourne, Australia, 23 September 2021

XETRA-DAX:

UR9

NASDAQ INTERNATIONAL DESIGNATION:

CLVLY

CLINUVEL PHARMACEUTICALS LTD (Company) today issued an updated schedule of key events and planned announcements for the remainder of calendar year 2021.

Calendar 2021

Event or Announcement

By early October

Operations Update II Webinar

By 08 October

Notice of Meeting

Appendix 4G and Corporate Governance

Annual Report 2021

15-30 October

Strategic Update III

News Communiqué V

22 October

Morgans Scone Value in the Vines Investment Conference

29 October

Appendix 4C, Quarterly Cash Receipts, September 2021

10 November

Annual General Meeting 2021

Chair's Address

MD's AGM Presentation

Results of Meeting

16-18 November 2021

Jefferies London Healthcare Conference

1-10 December

Chair's Letter

Mid December

News Communiqué VI

This schedule excludes specific announcements on the progress of CLINUVEL's clinical programs and operations.

- End -

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for targeted populations. As pioneers in photomedicine focussing on understanding the interaction of light and human biology, CLINUVEL's research and development has led to the world's first systemic photoprotective treatment. At present, CLINUVEL is developing afamelanotide and melanocortins to assist UV-induced DNA repair, and acute or life-threatening conditions, such as arterial ischemic stroke. The

Page 1 of 2

CLINUVEL Key Events and Announcements

eligible patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014, the US Food and Drug Administration in 2019 and the Australian Therapeutic Goods Administration in 2020 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore and the USA. For more information, please go to http://www.clinuvel.com.

SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries

https://www.clinuvel.com/investors/contact-us

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products, the COVID-19 pandemic affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg); our ability to achieve expected safety and efficacy results through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; any failure to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2021 Preliminary Final Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward- looking statement, whether as a result of new information, future events or otherwise. More information on the forecasts and estimates is available on request. Past performance is not an indicator of future performance.

www.clinuvel.com

Level 11

535 Bourke Street

Melbourne - Victoria, Australia, 3000

T +61 3 9660 4900

F +61 3 9660 4909

Page 2 of 2

CLINUVEL Key Events and Announcements

Disclaimer

Clinuvel Pharmaceuticals Limited published this content on 23 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 September 2021 23:51:06 UTC.


© Publicnow 2021
All news about CLINUVEL PHARMACEUTICALS LIMITED
10/17CLINUVEL PHARMACEUTICALS : Investor Webinar
PU
10/06CLINUVEL PHARMACEUTICALS : Operations Update Webcast II
PU
10/05Australia shares nearly flat as financials' losses offset tech, healthcare gains
RE
10/05CLINUVEL PHARMACEUTICALS : Secures Clearances for Phase Two Study of DNA Repair Drug
MT
10/04CLINUVEL PHARMACEUTICALS : Progresses DNA Repair Program
PU
10/04Clinuvel Pharmaceuticals Limited Receives the Necessary Regulatory and Ethics Committee..
CI
09/22CLINUVEL PHARMACEUTICALS : Key Events and Announcements
PU
09/21CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
09/13CLINUVEL PHARMACEUTICALS : Presentation H.C. Wainwright Global Investment Conference
PU
09/02CLINUVEL PHARMACEUTICALS LIMITED : Ex-dividend day for final dividend
FA
More news
Financials
Sales 2022 64,6 M 47,9 M 47,9 M
Net income 2022 30,9 M 22,9 M 22,9 M
Net cash 2022 108 M 80,1 M 80,1 M
P/E ratio 2022 66,4x
Yield 2022 0,11%
Capitalization 2 000 M 1 482 M 1 485 M
EV / Sales 2022 29,3x
EV / Sales 2023 20,2x
Nbr of Employees -
Free-Float 79,2%
Chart CLINUVEL PHARMACEUTICALS LIMITED
Duration : Period :
Clinuvel Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLINUVEL PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 40,48 AUD
Average target price 33,92 AUD
Spread / Average Target -16,2%
EPS Revisions
Managers and Directors
Philippe Jacques Wolgen Chief Executive Officer, MD & Director
Darren M. Keamy Chief Financial Officer & Secretary
Willem A. Blijdorp Chairman
Dennis J. Wright Chief Scientific Officer
Lachlan Hay Global Director-Operations
Sector and Competitors
1st jan.Capi. (M$)
CLINUVEL PHARMACEUTICALS LIMITED81.36%1 508
CSL LIMITED3.93%100 638
WUXI BIOLOGICS (CAYMAN) INC.11.77%59 673
SAMSUNG BIOLOGICS CO.,LTD.3.87%48 619
BIOGEN INC.14.84%41 907
ALEXION PHARMACEUTICALS, INC.0.00%40 336